Clinical Trial Update: Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update reports results for lenalidomide (Revlimid) in patients with relapsed or refractory indolent non-Hodgkin lymphoma; results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: Non-Hodgkins Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2013-10-14